Biotech Stocks Facing FDA Decision In March

After a banner year in 2018, the novel drug approval is off to an uncharacteristically slow start this year. No novel drug was approved in January while three were approved in February.

from RTT - Biotech https://ift.tt/2H1RIVo
via IFTTT